FDA approves restricted marketing of Lotronex.
D002243:Carbolines / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D002243:Carbolines; D005765:Gastrointestinal Agents; C090840:alosetron